<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1724">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04333472</url>
  </required_header>
  <id_info>
    <org_study_id>CF101-241COVID-19</org_study_id>
    <nct_id>NCT04333472</nct_id>
  </id_info>
  <brief_title>Piclidenoson for Treatment of COVID-19</brief_title>
  <official_title>Piclidenoson for Treatment of COVID-19 - A Randomized, Double-Blind, Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Can-Fite BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Can-Fite BioPharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with documented moderate COVID-19 infection will be randomized 1:1 to receive&#xD;
      piclidenoson 2 mg Q12H orally with standard supportive care (SSC - intervention arm) or&#xD;
      placebo orally with SSC (control arm) for up to 28 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, pilot trial of piclidenoson 2 mg Q12H&#xD;
      added to SSC, compared to placebo plus SSC, in a population of hospitalized subjects with&#xD;
      &quot;Moderate&quot; COVID-19 per U.S. National Institutes of Health (NIH) Coronavirus Disease 2019&#xD;
      (COVID-19) Treatment Guidelines (2020). Subjects will be randomized according to a 1:1 ratio&#xD;
      to one of the trial arms, and treated for up to 28 days, at the discretion of the&#xD;
      Investigator. Piclidenoson 2 mg and placebo are supplied as matching tablets for oral&#xD;
      administration.&#xD;
&#xD;
      Following initial diagnosis of COVID-19, and after having provided informed consent, subjects&#xD;
      will be randomized according to 1:1 ratio to one of the trial arms on Day 0. SSC will be&#xD;
      implemented and documented for all subjects, and maintained throughout the treatment period.&#xD;
&#xD;
      Vital signs (temperature, blood pressure, pulse rate per minute, respiratory rate per minute,&#xD;
      oxygen saturation (SpO2), and PaO2/FiO2) of subjects will be monitored twice daily according&#xD;
      to SSC. Parameters of clinical, respiratory, and vital status will be collected daily. Viral&#xD;
      shedding will be assessed on a regular basis. Samples for pharmacokinetic (PK) analysis will&#xD;
      be collected on Day 4.&#xD;
&#xD;
      Efficacy of piclidenoson will be assessed by clinical, respiratory, and virologic parameters.&#xD;
      Safety and tolerability of piclidenoson will be assessed by adverse event (AE) monitoring,&#xD;
      vital signs assessment, electrocardiograms (ECGs), and clinical laboratory tests (complete&#xD;
      blood count (CBC) and extended chemistry panel). Adverse events will be graded by the Common&#xD;
      Terminology Criteria for Adverse Events (CTCAE v5.0).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2021</start_date>
  <completion_date type="Anticipated">July 6, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 6, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects alive and free of respiratory failure</measure>
    <time_frame>29 days</time_frame>
    <description>Proportion of subjects alive and free of respiratory failure (defined as need for non-invasive or invasive mechanical ventilation, high-flow oxygen, or extracorporeal membrane oxygenation) at Day 29</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects discharged home alive</measure>
    <time_frame>29 days</time_frame>
    <description>Proportion of subjects alive and discharged to home without need for supplemental oxygen at Day 29</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment-emergent adverse events (AEs)</measure>
    <time_frame>29 days</time_frame>
    <description>Proportion of patients experiencing AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical status</measure>
    <time_frame>29 days</time_frame>
    <description>• Clinical status at Day 29 on NIAID 8-point ordinal scale (NIH 2020):&#xD;
Not hospitalized, no limitations&#xD;
Not hospitalized, with limitations&#xD;
Hospitalized, no active medical problems&#xD;
Hospitalized, not on oxygen&#xD;
Hospitalized, on oxygen&#xD;
Hospitalized, on high-flow oxygen or noninvasive mechanical ventilation&#xD;
Hospitalized, on mechanical ventilation or ECMO&#xD;
Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to improvement</measure>
    <time_frame>29 days</time_frame>
    <description>Time (days) to improvement of 2 points on 7-point ordinal clinical scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of mechanical ventilation</measure>
    <time_frame>29 days</time_frame>
    <description>Proportion of patients who require mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days</measure>
    <time_frame>29 days</time_frame>
    <description>Ventilator-free days to Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Intensive Care Unit (ICU) admission</measure>
    <time_frame>29 days</time_frame>
    <description>Proportion of patients who require ICU admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU stay</measure>
    <time_frame>29 days</time_frame>
    <description>Duration (days) of ICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to hospital discharge</measure>
    <time_frame>29 days</time_frame>
    <description>Time (days) to hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of need for supplemental oxygen</measure>
    <time_frame>29 days</time_frame>
    <description>Duration (days) of need for supplemental oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to virus negativity</measure>
    <time_frame>29 days</time_frame>
    <description>Time (days) to virus negativity by RT-PCR, defined as absence of SARS CoV 2 on 2 consecutive days of sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 viral load</measure>
    <time_frame>29 days</time_frame>
    <description>SARS-CoV-2 viral load (number of copies) by quantitative RT-PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs leading to withdrawal</measure>
    <time_frame>29 days</time_frame>
    <description>Proportion of patients experiencing AEs leading to early discontinuation of trial treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent serious AEs (SAEs)</measure>
    <time_frame>29 days</time_frame>
    <description>Proportion of patients experiencing SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent abnormalities in clinical laboratory parameters or electrocardiograms (ECGs)</measure>
    <time_frame>29 days</time_frame>
    <description>Proportion of patients experiencing treatment-emergent changes in clinical laboratory parameters or ECGs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of meeting safety-related stopping rules</measure>
    <time_frame>29 days</time_frame>
    <description>Proportion of patients who meet study safety-related stopping rules</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of piclidenoson in this patient population</measure>
    <time_frame>5 days</time_frame>
    <description>Plasma concentrations over time of piclidenoson</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum cytokine levels</measure>
    <time_frame>29 days</time_frame>
    <description>Change from baseline in serum concentrations of cytokines</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>COVID-19</condition>
  <condition>Coronavirus Infection</condition>
  <arm_group>
    <arm_group_label>Piclidenoson</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Piclidenoson 2 mg every 12 hours orally added to standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo every 12 hours orally added to standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piclidenoson</intervention_name>
    <description>Piclidenoson 2 mg orally every 12 hours for up to 28 days</description>
    <arm_group_label>Piclidenoson</arm_group_label>
    <other_name>CF101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo orally every 12 hours for up to 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. 18-85 years of age&#xD;
&#xD;
          2. Able and willing to sign informed consent&#xD;
&#xD;
          3. Molecular (RT-PCR) diagnosis of SARS-CoV-2 infection&#xD;
&#xD;
          4. Moderate illness per NIH COVID-19 Treatment Guidelines:&#xD;
&#xD;
               -  Symptoms such as cough, fever, sore throat, malaise, myalgias, headache; and&#xD;
&#xD;
               -  Evidence of lower respiratory tract disease by clinical assessment and/or&#xD;
                  imaging; and&#xD;
&#xD;
               -  SpO2 &gt;93% on room air at sea level&#xD;
&#xD;
          5. Female subjects must have a negative serum pregnancy test (minimum sensitivity 25 IU/L&#xD;
             or equivalent units of human chorionic gonadotropin) within 24 hours prior to the&#xD;
             start of investigational product&#xD;
&#xD;
          6. Female subjects of childbearing potential and male subjects with partners of&#xD;
             childbearing potential must agree to use adequate methods of contraception during the&#xD;
             study and through 90 days after the last dose of study medication. Female subjects of&#xD;
             childbearing potential are all those except subjects who are surgically sterile, who&#xD;
             have medically documented ovarian failure, or who are at least 1 year postmenopausal.&#xD;
&#xD;
               1. For females: 2 of the following contraceptive methods, with at least 1 being a&#xD;
                  barrier method:&#xD;
&#xD;
                    -  Hormonal contraceptives for at least 27 days before dosing&#xD;
&#xD;
                    -  Intrauterine device (IUD) in place at least 27 days before dosing&#xD;
&#xD;
                    -  Double-barrier methods (use of condom [male partner] with either diaphragm&#xD;
                       with spermicide or cervical cap with spermicide) from screening&#xD;
&#xD;
                    -  Surgical sterilization of the partner (vasectomy at least 1 month before&#xD;
                       screening)&#xD;
&#xD;
                    -  Female subjects must have a negative urine pregnancy test (minimum&#xD;
                       sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin)&#xD;
                       within 24 hours prior to the start of investigational product.&#xD;
&#xD;
               2. For males: Surgical sterilization (vasectomy at least 1 month before screening)&#xD;
                  or double barrier methods.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Severe illness, including any of the following:&#xD;
&#xD;
               -  Respiratory rate &gt;30 breaths/minute; or&#xD;
&#xD;
               -  SpO2 ≤93% on room air at sea level; or&#xD;
&#xD;
               -  Ratio of arterial partial pressure of oxygen to fraction of inspired oxygen&#xD;
                  (PaO2/FiO2) &lt;300; or&#xD;
&#xD;
               -  Lung infiltrates &gt;50% of pulmonary volume on imaging&#xD;
&#xD;
          2. Critical illness, including any of the following:&#xD;
&#xD;
               -  Respiratory failure; or&#xD;
&#xD;
               -  Septic shock; or&#xD;
&#xD;
               -  Multiple organ dysfunction&#xD;
&#xD;
          3. Participation in another clinical trial concurrently&#xD;
&#xD;
          4. Concurrent treatment with immunomodulators or anti-rejection drugs&#xD;
&#xD;
          5. Nursing women, pregnant women, women of childbearing potential who do not want&#xD;
             adequate contraception&#xD;
&#xD;
          6. History of any of the following diseases or conditions:&#xD;
&#xD;
               -  Advanced or decompensated liver disease (including presence or history of&#xD;
                  bleeding varices, ascites, encephalopathy, or hepato-renal syndrome)&#xD;
&#xD;
               -  Inability to swallow tablets, or gastrointestinal disease which could interfere&#xD;
                  with the absorption of piclidenoson&#xD;
&#xD;
               -  Any malignancy within 5 years before screening; exceptions are superficial&#xD;
                  dermatologic malignancies (e.g., squamous cell or basal cell skin cancer treated&#xD;
                  with curative intent)&#xD;
&#xD;
               -  Cardiomyopathy, significant ischemic cardiac or cerebrovascular disease&#xD;
                  (including history of angina, myocardial infarction, or interventional procedure&#xD;
                  for coronary artery disease), or cardiac rhythm disorder&#xD;
&#xD;
               -  QTcF interval on an average of triplicate ECGs &gt;450 milliseconds (msec) for males&#xD;
                  or &gt;470 msec for females (except when QT prolongation is associated with right or&#xD;
                  left bundle branch block, in which case enrollment is allowed)&#xD;
&#xD;
               -  Any condition which increases proarrhythmic risk, including hypokalemia,&#xD;
                  hypomagnesemia, congenital Long QT Syndrome&#xD;
&#xD;
               -  Ongoing or planned use of a concomitant medication that is on the CredibleMeds&#xD;
                  list of drugs known to cause Torsades de Pointes unless the subject can be&#xD;
                  screened and monitored under the guidelines proposed by Giudicessi (2020)&#xD;
&#xD;
               -  Pancreatitis&#xD;
&#xD;
               -  Severe or uncontrolled psychiatric disorder, e.g., depression, manic condition,&#xD;
                  psychosis, acute and/or chronic cognitive dysfunction, suicidal behavior, and&#xD;
                  relapse of substance abuse&#xD;
&#xD;
               -  Active seizure disorder defined by either an untreated seizure disorder or&#xD;
                  continued seizure activity within the preceding year despite treatment with&#xD;
                  anti-seizure medication&#xD;
&#xD;
               -  Bone marrow or solid organ transplantation&#xD;
&#xD;
               -  Any serious condition that, in the opinion of the investigator, would preclude&#xD;
                  evaluation of response or make it unlikely that the contemplated course of&#xD;
                  therapy and follow-up could be completed&#xD;
&#xD;
          7. Any of the following abnormal laboratory tests:&#xD;
&#xD;
               -  Platelet count &lt;90,000 cells/mm3&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &lt;1,500 cells/mm3&#xD;
&#xD;
               -  Estimated creatinine clearance (CrCl) &lt;50 mL/min by Cockroft-Gault formulation&#xD;
&#xD;
               -  Bilirubin level ≥2.5 mg/dL unless due to Gilbert's syndrome&#xD;
&#xD;
               -  AST or ALT level ≥3X the upper limit of normal&#xD;
&#xD;
               -  Serum albumin level &lt;3.0 g/dL&#xD;
&#xD;
               -  International normalized ratio (INR) ≥1.5 (except subjects maintained on&#xD;
                  anticoagulant medications)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zivit Harpaz</last_name>
    <role>Study Director</role>
    <affiliation>Can-Fite BioPharma Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zivit Harpaz</last_name>
    <phone>+972-3-9241114</phone>
    <email>Zivit@canfite.co.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoseph Caraco, MD</last_name>
      <phone>+972-2-6778584</phone>
      <email>caraco@hadassah.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramzi Kurd, MD</last_name>
      <phone>+972-52-2362671</phone>
      <email>ramzik@szmc.org.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>http://canfite.co.il</url>
    <description>Sponsor website</description>
  </link>
  <reference>
    <citation>Fishman P, Cohen S. The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis. Clin Rheumatol. 2016 Sep;35(9):2359-62. doi: 10.1007/s10067-016-3202-4. Epub 2016 Feb 17. Review.</citation>
    <PMID>26886128</PMID>
  </reference>
  <reference>
    <citation>Cohen S, Fishman P. Targeting the A(3) adenosine receptor to treat cytokine release syndrome in cancer immunotherapy. Drug Des Devel Ther. 2019 Jan 30;13:491-497. doi: 10.2147/DDDT.S195294. eCollection 2019. Review.</citation>
    <PMID>30787591</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2020</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Piclidenoson</keyword>
  <keyword>CF101</keyword>
  <keyword>SARS-CoV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>To be determined</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>January 2021, indefinitely</ipd_time_frame>
    <ipd_access_criteria>To be determined</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

